Nav: Home

Costs of similarly effective breast cancer treatments vary widely

October 10, 2016

A new study finds that the costs of breast cancer chemotherapy vary widely, even among treatment regimens with similar efficacy, and that patients bear a substantial out-of-pocket burden. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study is the first to examine these cost differences, providing clinicians with accessible information to answer patient questions about their treatment options.

To estimate the costs to payers and patients for breast cancer treatment regimens, Sharon Giordano, MD, MPH, of The University of Texas MD Anderson Cancer Center in Houston, and her colleagues assessed information on 14,643 women who were diagnosed with breast cancer between 2008 and 2012 and who received chemotherapy within three months of diagnosis. Total and out-of-pocket costs were calculated using all claims within 18 months of diagnosis and were normalized to 2013 dollars.

Among the major findings:
  • Among patients who did and did not receive trastuzumab, which targets the HER2 protein that is over-expressed in certain types of breast cancer cells, the median insurance payments were $160,590 and $82,260,respectively.
  • For patients who did not receive trastuzumab, the median out-of-pocket payment was $2724 and 10 percent of patients paid more than $7041.
  • For patients treated with trastuzumab, the median out-of-pocket payment was $3381 and 10 percent paid more than $8384.
  • Among patients on high deductible health plans, the median out-of-pocket cost was $5158 and 10 percent of patients paid $11,344 or more.
"We found a wide variation in costs between these regimens, which could result in unnecessary costs to both patients and the health care system," said Dr. Giordano. "We also found that many patients had high out of pocket costs for their care." The authors noted that the use of an equally effective but less costly treatment regimen versus the most expensive regimen could reduce national costs of breast cancer care by more than $1 billion each year.

Dr. Giordano added that the costs of cancer care have continued to rise and these costs can place a substantial burden on patients and their families. "The Institute of Medicine has recommended that the costs of care be discussed with patients, and we hope that our findings can be used to inform discussions with patients and promote well-informed shared decisions regarding treatment."
-end-
Full Citation: "Estimating Regimen-Specific Costs of Chemotherapy for Breast Cancer: Observational Cohort Study." Sharon H. Giordano, Jiangong Niu, Mariana Chavez-MacGregor, Hui Zhao, Daria Zorzi, Ya-Chen Tina Shih, Benjamin Smith, and Chan Shen. CANCER; Published Online: October 10, 2016 (DOI: 10.1002/cncr.30274).

Author Contact: Clayton R. Boldt, PhD, The University of Texas MD Anderson Cancer Center's Senior Communications Specialist, at crboldt@mdanderson.org or +1 (713) 792-9518.

About the Journal

CANCER is a peer-reviewed publication of the American Cancer Society integrating scientific information from worldwide sources for all oncologic specialties. The objective of CANCER is to provide an interdisciplinary forum for the exchange of information among oncologic disciplines concerned with the etiology, course, and treatment of human cancer. CANCER is published on behalf of the American Cancer Society by Wiley and can be accessed online at http://wileyonlinelibrary.com/journal/cancer.

Follow us on Twitter @JournalCancer and Facebook https://www.facebook.com/ACSJournals

About Wiley

Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical, and scholarly journals, combined with our digital learning, assessment and certification solutions help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders.

Wiley

Related Breast Cancer Articles:

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.
Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.
More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.
Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.
Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.
Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.
Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.
Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.
Does MRI plus mammography improve detection of new breast cancer after breast conservation therapy?
A new article published by JAMA Oncology compares outcomes for combined mammography and MRI or ultrasonography screenings for new breast cancers in women who have previously undergone breast conservation surgery and radiotherapy for breast cancer initially diagnosed at 50 or younger.
Blood test offers improved breast cancer detection tool to reduce use of breast biopsy
A Clinical Breast Cancer study demonstrates Videssa Breast can inform better next steps after abnormal mammogram results and potentially reduce biopsies up to 67 percent.
More Breast Cancer News and Breast Cancer Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.